SCHEMBL15845873

SCHEMBL15845873

CN(C)CCOCc1ccccc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.59
HTR7 P34969 3/20 0.54
IDO1 P14902 2/20 0.48
UTS2R Q9UKP6 1/20 0.45
TSHR P16473 3/20 0.42
DRD1 P21728 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
USP2 O75604 1/20 0.41
CHRM2 P08172 2/20 0.41
ADRA2A P08913 2/20 0.41
CHRM1 P11229 2/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
OPRM1 P35372 2/20 0.41
DRD3 P35462 2/20 0.41
SLC6A3 Q01959 2/20 0.41
HTR1A P08908 1/20 0.41
TBXA2R P21731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153147 0.83 TSHR (0.60) TAAR1IDO1TSHRDRD1DRD2
SCHEMBL18171748 0.82 IDO1 (0.61) TAAR1IDO1TSHRPYCR1CHRM3
SCHEMBL7222677 0.79 IDO1 (0.53) TAAR1IDO1TSHRLMNACYP1A2
SCHEMBL18171753 0.79 IDO1 (0.57) TAAR1IDO1TSHRCHRM3HTT
SCHEMBL18171754 0.79 IDO1 (0.57) TAAR1IDO1TSHRCHRM3HTT
SCHEMBL3865796 0.78 IDO1 (0.67) TAAR1IDO1TSHRPYCR1CHRM3
SCHEMBL18343943 0.78 IDO1 (0.52) TAAR1IDO1TSHRCHRM3HTT
SCHEMBL2400375 0.77 IDO1 (0.55) TAAR1IDO1TSHRCHRM3HTT
SCHEMBL15845948 0.77 IDO1 (0.55) TAAR1IDO1TSHRLMNACYP1A2
SCHEMBL9419149 0.77 IDO1 (0.59) TAAR1IDO1TSHRLMNAPYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 TAAR1 1584/4885HTR7 193/4885IDO1 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.